home / lobbying / lobbying_activities

lobbying_activities: 3193086

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id filing_uuid filing_type registrant_name registrant_id client_name filing_year filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
3193086 54f41762-6440-4e9d-b5b3-f6b156a19d08 Q2 AMERICAN SOCIETY OF ADDICTION MEDICINE 401104864 AMERICAN SOCIETY OF ADDICTION MEDICINE 2024 second_quarter INS Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for at least $10.5 billion for HRSA programs in the FY 2025 Labor, Health and Human Services, Education, and Related Agencies appropriations bill. Joined coalition letter opposing any legislation that would bar medical schools from receiving federal funding if they engage in activities such as having a Diversity, Equity and Inclusion (DEI) office and/or provide education on structural or institutional racism. Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for draft legislation that would provide Medicare coverage for evidence-based residential SUD services. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Suggested additional regulatory changes to SAMHSA related to opioid treatment programs and the provision of methadone for opioid use disorder. Joined a coalition letter urging support of the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Joined a coalition letter requesting clear guidance from the relevant agencies that explicitly states that suspicious order reporting requirements will not be enforced against buprenorphine approved by the Food and Drug Administration (FDA) for OUD until further notice. Joined a coalition letter calling on the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Joined a coalition letter urging the House Appropriations Committee's approval of the full authorized level of tobacco user fees, and that they oppose any efforts to weaken or alter the Food and Drug Administration's authority over tobacco products in the appropriations process. Joined a coalition letter urging the Centers for Medicare and Medicaid Services (CMS) to improve data collection on access to substance use disorder (SUD) treatment and providers, and to use this data to continue to improve access to SUD treatment in both Medicare Advantage (MA) and traditional Medicare. The letter asks CMS to collect data on network adequacy, reimbursement rates and practices, utilization management, cost-sharing, and supplemental benefits. Sent a comment letter to HRSA on its draft program guidance regarding justice-involved individuals reentering the community ASAM noted the exclusion of pre-trial detainees from this guidance and called on HRSA rescind the omission. Sent a comment letter to the Centers for Medicare and Medicaid Services (CMS) regarding a proposed rule to implement 200 new residency/fellowship slots by fiscal year 2026. ASAM called on CMS to work with HRSA to revise the mental health health professional shortage area (HPSA) definition and related criterion to include clinicians that specialize in treating SUD. Joined a coalition letter requesting the Departments of Health and Human Services, Labor, and Treasury finalize the 2023 proposed parity regulations. Joined a coalition letter requesting $40 million for the Employee Security Benefits Administration (EBSA) within the Department of Labor (DOL) in the FY 2025 Labor-Health and Human Services (HHS) appropriations bill to review health plans' parity compliance analyses. Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA)   40000 0 0 2024-07-16T06:55:29-04:00
Powered by Datasette · Queries took 15.178ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API